Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$38.76 USD

38.76
1,334,792

-0.40 (-1.02%)

Updated Jul 15, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GSK (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $33.27 in the latest trading session, marking a +1.68% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod

by Kinjel Shah

Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $32.24 in the latest trading session, marking a +1.51% move from the prior day.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $31.31, moving +0.19% from the previous trading session.

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults

by Zacks Equity Research

GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK

by Zacks Equity Research

Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.

GSK (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $30.65 in the latest trading session, marking a +0.92% move from the prior day.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab

by Kinjel Shah

FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.

Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review

by Zacks Equity Research

Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.

Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?

by Zacks Equity Research

Gilead (GILD) is having a good run despite the volatility on a string of positive updates.

GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns

by Zacks Equity Research

Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $30.11, moving +0.37% from the previous trading session.

Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract

by Zacks Equity Research

VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.

GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal

by Zacks Equity Research

GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.

GSK (GSK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $30.41, marking a -0.98% move from the previous day.

GSK's Key Drugs to Drive Sales in a Sluggish Second Half

by Zacks Equity Research

GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.

Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth

by Zacks Equity Research

Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong.

Here is What to Know Beyond Why GSK PLC Sponsored ADR (GSK) is a Trending Stock

by Zacks Equity Research

Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

GSK (GSK) Stock Moves -0.34%: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $29.36 in the latest trading session, marking a -0.34% move from the prior day.

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

by Zacks Equity Research

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK

by Kinjel Shah

Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $30.01, marking a +0.81% move from the previous day.